Anti-seizure Medications: Challenges and Opportunities
- PMID: 38192128
- DOI: 10.2174/0118715273275793231030060833
Anti-seizure Medications: Challenges and Opportunities
Abstract
Epilepsy is a chronic neurological condition characterized by unprovoked, recurrent seizures. There are several types of epilepsy, and the cause of the condition can vary. Some cases of epilepsy have a genetic component, while others may be caused by brain injuries, infections, or other underlying conditions. Treatment for epilepsy typically involves anti-seizure medications (ASMs), although different approaches, such as surgery or a special diet, may be considered in specific cases. The treatment aims to effectively manage and potentially eliminate seizures while minimizing any accompanying side effects. Many different ASMs are available, and the choice of medication depends on several factors, including the type of seizures, the patient's age, general health, and potential drug interactions. For the treatment of epilepsy, there have been significant advancements in recent decades, which have led to the approval of many different ASMs. Newer ASMs offer a broader range of mechanisms of action, improved tolerability profiles, and reduced drug interactions compared to older drugs. This review aims to discuss the pharmacological characteristics, clinical applications, effectiveness, and safety of ASMs, with a particular emphasis on various age groups, especially children. Moreover, this review seeks to provide a comprehensive understanding of ASM therapy for epilepsy management, assisting physicians in selecting suitable ASMs for their patients.
Keywords: Epilepsy; anti-seizure medications; neuropharmacology.; pharmacotherapy; precision medicine; seizures.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Patterns of anti-seizure medication (ASM) use in pediatric patients with surgically managed epilepsy: A retrospective review of data from Boston Children's Hospital.Epilepsy Res. 2020 Feb;160:106257. doi: 10.1016/j.eplepsyres.2019.106257. Epub 2020 Jan 8. Epilepsy Res. 2020. PMID: 32004867
-
An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug resistant epilepsy in the United States.J Med Econ. 2023 Jan-Dec;26(1):189-199. doi: 10.1080/13696998.2023.2171230. J Med Econ. 2023. PMID: 36691763
-
Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures.Epilepsia Open. 2024 Jun;9(3):1051-1058. doi: 10.1002/epi4.12936. Epub 2024 Apr 4. Epilepsia Open. 2024. PMID: 38573131 Free PMC article.
-
What has been the impact of new drug treatments on epilepsy?Curr Opin Neurol. 2020 Apr;33(2):185-190. doi: 10.1097/WCO.0000000000000803. Curr Opin Neurol. 2020. PMID: 32049739 Review.
-
[The Basis of Medication Therapy for Epilepsy].No Shinkei Geka. 2023 Jan;51(1):95-104. doi: 10.11477/mf.1436204720. No Shinkei Geka. 2023. PMID: 36682754 Review. Japanese.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical